Investor Relations

Tempest Therapeutics is a clinical-stage CAR-T company building the future of in vivo CAR-T therapy for oncology and immunology applications with a clinically validated dual-targeting CD19/BCMA CAR construct and differentiated CD7-targeted mRNA/LNP delivery approach.